Advanced hepatocellular carcinoma
Get Latest Price
Minimum Order Quantity: 3 Bottle
|Packaging size||28 tablets per bottle|
|Treatment||Advanced hepatocellular carcinoma|
|Generic Name||Regorafenib 40mg|
Regorafenib (commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had 2 US approvals for advanced cancers.
View Complete Details